I-131-Apamistamab - Actinium Pharmaceuticals

Drug Profile

I-131-Apamistamab - Actinium Pharmaceuticals

Alternative Names: 131-I-labeled anti-CD45 antibody; 131-I-labeled BC8 antibody; 131I-BC8 (anti-CD45) antibody - Actinium Pharmaceuticals; Anti-CD45 monoclonal antibody-BC8-I-131; Anti-CD45 monoclonal antibody-I-131; BC 8; BC8-I-131 construct; I131-Apamistamab; Iomab-B

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Fred Hutchinson Cancer Research Center
  • Developer Actinium Pharmaceuticals; Fred Hutchinson Cancer Research Center
  • Class Antineoplastics; Immunoconjugates; Immunotherapies; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action CD45 antigen inhibitors; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase II Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase I Hodgkin's disease; Non-Hodgkin's lymphoma

Most Recent Events

  • 25 Jan 2018 Actinium Pharmaceuticals announces intention to submit BLA to US FDA for Acute myeloid leukaemia in 2018
  • 13 Nov 2017 Actinium Pharmaceuticals announces intention to submit MAA to EMA for Acute myeloid leukaemia
  • 15 Jun 2017 Anti-CD45 monoclonal-antibody BC8-I-131 is available for licensing in Europe, USA as of 15 June 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top